Cord Blood Transplant for Adults with Blood Cancers

Sponsor: Memorial Sloan Kettering Cancer Center

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT05884333

Provider View

This study is collecting information on the outcomes of cord blood transplants in adults with blood cancers, using a standard practice developed by MSK. The research focuses on side effects, disease relapse, and recovery of the immune system after the transplant.

Patient Parameters

Program Overview

Cord blood transplants are a common treatment for adults with blood cancers. This study uses a standard method developed by MSK to perform these transplants. The process includes evaluating patients, preparing them with chemotherapy and radiation, and monitoring them after the transplant. The study aims to gather data on how well patients do after receiving a cord blood transplant, including any side effects, chances of the cancer returning, and how the immune system recovers.

Eligibility Criteria

Inclusion Criteria

  • Adults with certain types of blood cancers, such as acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL), who are at high risk of the cancer returning.
  • Patients with other acute leukemias or myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPD) that meet specific risk criteria.
  • Patients with non-Hodgkin lymphoma (NHL) at high risk of relapse or progression.
  • Patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in remission.
  • Must have good organ function and performance status, as measured by specific medical tests.
  • Must meet specific criteria for the cord blood units used in the transplant, including matching and cell dose requirements.

Exclusion Criteria

  • Patients with myelofibrosis or other cancers with significant bone marrow fibrosis.
  • Patients with active cancer in the central nervous system.
  • Patients who have had certain treatments, like checkpoint inhibitors, in the last year.
  • Patients who have had two previous stem cell transplants or one within the last year.
  • Patients with a history of certain infections or inadequate organ function.
  • Pregnant or breastfeeding women.
  • Patients unable to give informed consent or follow the treatment plan.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.